Clinical trial
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of…
NCT00492388 · Hospira, now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00492388 |
|---|---|
| Title | Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients |
| Lead sponsor | Hospira, now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Cancer |
| Intervention type | Drug |
| Interventions | PMI-150 (intranasal ketamine), placebo |
| Enrollment | 2 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: